100141-30-8

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-TERT-BUTYL-2-CHLOROPHENYL)ACETAMIDE is used as a potential drug candidate for the development of new medications due to its unique chemical structure and potential pharmacological properties.
Used in Organic Synthesis:
N-(4-TERT-BUTYL-2-CHLOROPHENYL)ACETAMIDE is used as an intermediate in the synthesis of other organic compounds, particularly in the preparation of various organic molecules, leveraging its reactivity conferred by the chlorophenyl group.
The specific applications and reasons for using N-(4-TERT-BUTYL-2-CHLOROPHENYL)ACETAMIDE in the pharmaceutical industry or organic synthesis are not explicitly provided in the materials. However, the compound's unique structure and potential properties suggest its utility in these areas.

Upstream product

• 42265-67-8 4-t-butyl-2-chloroaniline 
• 75-36-5 acetyl chloride 
• 769-92-6 4-tert-Butylaniline 
• 20330-45-4 4-tert-butylacetanilide 

Downstream Products

• 42265-67-8 4-t-butyl-2-chloroaniline 
• 945012-60-2 C₁₂H₁₈NCl 
• 1338065-15-8 1-[(4-tert-butyl-2-pyrrolidin-1-yl-phenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea 
• 1338065-78-3 (4-tert-butyl-2-pyrrolidin-1-yl-phenyl)methanamine 
• 1338065-77-2 4-tert-butyl-2-pyrrolidin-1-yl-benzonitrile 
• 1338065-75-0 C₁₁H₁₆ClN 
• 67740-14-1 C₁₁H₁₂ClN 
• 1338065-14-7 1-[(4-tert-butyl-2-chloro-phenyl)methyl]-3-(2-oxo-1,3-dihydrobenzimidazol-4-yl)urea 
• 7498-54-6 3-t-Butylbenzoic acid 
• 3972-55-2 1-tert-butyl-3-chloro-benzene 
• 2359-09-3 5-t-butylisophthalic acid 

Relevant academic research and scientific papers

"TRPV1 VANILLOID RECEPTOR ANTAGONISTS WITH A BICYCLIC PORTION"

The invention discloses compounds of formula I wherein Y is a group of formula A, B, C, D, or E: and W, Q, n, R1, R2, R3, U1-U5, J and K have the meanings given in the description. The compounds of formula I are TRPV1 antagonists and are useful as active

Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors

High-throughput screening hit 1 was identified as a potent, broad-spectrum, non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 replication. Analysis of the bound conformation of analogs of this inhibitor via molecular modeling and NMR contrib

NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

The invention relates to compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and, pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV for the treatment or prophylaxis of HIV infection